Skip to Content
Careers
Search
Search
ABOUT BIORASI
LEADERSHIP AND SCIENTIFIC ADVISORS
WHY BIORASI
PARTNERSHIP
TESTIMONIALS
THERAPEUTIC EXPERTISE
DERMATOLOGY
ONCOLOGY
NEPHROLOGY
NEUROLOGY
CELL THERAPY
FOCUSED SOLUTIONS
RESCUE & RECOVERY
DATA SCIENCES
QUALITY
FEASIBILITY
SAFETY & PHARMACOVIGILANCE
CLINICAL MONITORING
PODCAST
RESOURCE LIBRARY
CONTACT US
ABOUT BIORASI
LEADERSHIP AND SCIENTIFIC ADVISORS
WHY BIORASI
PARTNERSHIP
TESTIMONIALS
THERAPEUTIC EXPERTISE
DERMATOLOGY
ONCOLOGY
NEPHROLOGY
NEUROLOGY
CELL THERAPY
FOCUSED SOLUTIONS
RESCUE & RECOVERY
DATA SCIENCES
QUALITY
FEASIBILITY
SAFETY & PHARMACOVIGILANCE
CLINICAL MONITORING
PODCAST
RESOURCE LIBRARY
CONTACT US
Resource • White Paper
Optimizing the Amount of Investigational Materials in ANDA Studies – Part Two
July 12th, 2017
|
ANDA
|
White Paper
For Dermal Semisolid Clinical Studies White Paper Series
Download White Paper
Get Access to this White Paper Now
Share this Story
Related Resources
White Paper
FROM PROMISE TO PROGRAM
Building Credible Paths to the Next Value Inflection
White Paper
Spotlight on India: Regulatory Enhancements, Modernization, and Robust Data Collection Define India as a Potential Clinical Trial Hub
View All